Precision oncology with selective RET inhibitor selpercatinib in <i>RET</i>-rearranged cancers.

"The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Vivek Subbiah reports research funding/grant support for clinical trials from AbbVie, Agensys, Inc., Alfasigma, Altum, Amgen, Bayer, BERG Health, Blueprint Medicines Corporation, Boston Biomedical, Inc., Boston Pharmaceuticals, Celgene Corporation, D3 Bio, Inc., Dragonfly Therapeutics, Inc., Exelixis, Fujifilm, GlaxoSmithKline, Idera Pharmaceuticals, Inc., Incyte Corporation, Inhibrx, Loxo Oncology, MedImmune, MultiVir, Inc., NanoCarrier, Co., National Comprehensive Cancer Network, NCI-CTEP, Northwest Biotherapeutics, Novartis, PharmaMar, Pfizer, Relay Therapeutics, Roche/Genentech, Takeda, Turning Point Therapeutics, UT MD Anderson Cancer Center, and Vegenics Pty Ltd.; travel support from ASCO, ESMO, Helsinn Healthcare, Incyte Corporation, Novartis, and PharmaMar; consultancy/advisory board participation for Helsinn Healthcare, Jazz Pharmaceuticals, Incyte Corporation, Loxo Oncology/Eli Lilly, MedImmune, Novartis, QED Therapeutics, Relay Therapeutics, Daiichi-Sankyo, and R-Pharm US; and other relationship with Medscape. Mohamed Gouda has no conflicts of interest to disclose."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: V. Subbiah was at UT MD Anderson Cancer Center, Houston, TX, USA when this article was submitted and is currently affiliated to Sarah Cannon Research Institute, Nashville, TN, USA when this article was published. V. Subbiah is an Andrew Sabin Family Foundation Fellow at The University of Texas MD Anderson Cancer Center. V. Subbiah acknowledges the support of The Jacquelyn A. Brady Fund. V. Subbiah is supported by NIH grants (R01CA242845 and R01CA273168); the MD Anderson Cancer Center Department of Investigational Cancer Therapeutics is supported by the Cancer Prevention & Research Institute of Texas (RP1100584), the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (1U01 CA180964), a National Center for Advancing Translational Sciences Clinical and Translational Science Award (UL1 TR000371), and an MD Anderson Cancer Center Support Grant (P30 CA016672)."